Clinical trial · Observational
A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR)
Long-term Follow-up of Ipilimumab-treated Pediatric Patients Enrolled in the Dutch Melanoma Treatment Registry (DMTR)
NCT04196452CI-TRIAL-00097651active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an observational, national, retrospective study consisting of pediatric patients with advanced (spread or unremoveable) melanoma identified in the DMTR in the Netherlands
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ipilimumab | Drug | Ipilimumab | ALIAS |
Design
Arms and outcomes
Arms (2)
- label
- Arm A: participants 12 to under 18
- interventionNames
- Drug: Ipilimumab
- label
- Arm B: participants under 12
- interventionNames
- Drug: Ipilimumab
Primary outcomes (1)
- measure
- Frequency of Adverse Events (AEs) Grades 3-4
- timeFrame
- up to 10 years
Secondary outcomes (12)
- measure
- Baseline assessment of population demographics
- timeFrame
- up to 10 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 18 Years
Show eligibility criteria text
For more information regarding Bristol-Myers Squibb Clinical Trials, please visit www.BMSStudyConnect.com. Inclusion Criteria: * Less than 18 years of age at first dose of monotherapy Ipilimumab used for treatment of advanced melanoma * Histological or cytological confirmation of advanced (unresectable or metastatic) melanoma Exclusion Criteria: -Participation in a clinical trial within the past 4 weeks prior to first dose with ipilimumab or concurrently Other inclusion/exclusion criteria apply
References
Publications (0)
Data not yet available
No reference posted for this study.